ImmunoGuide® Enzyme immunoassay (ELISA) for the specific determination of free Nivolumab in serum and plasma.<br><br>
The drug Nivolumab (Opdivo®) is a fully human IgG4 monoclonal antibody that binds specifically to programmed death-1 (PD-1), a negative regulatory receptor expressed by activated T and B lymphocytes. Binding of Nivolumab to the PD-1 receptor blocks its interaction with the ligands, PDL1 and PD-L2, thereby attenuating PD-1–mediated inhibition of the immune response, including the anti-tumor immune response.<br><br>
The specificity of this test system is achieved by using a monoclonal antibody named "NY-11C3" for the coating of the microtiter plate.<br><br>
This antibody is specific for Nivolumab only and does not cross react with other PD-1 catchers. For research use only, not for use in diagnostic procedures.
- Assay Description:
- 1 hour incubation (RT) + 30 min. (RT) + 10 min. (RT) = 1 hour, 40 min. total incubation time
- Catalog number:
- TM09029
- configuration:
- 96 Determinations, 12x8 removable strips
- controls:
- None provided
- design:
- Enzyme immunoassay (ELISA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- Available upon request
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Opdivo®
- Protocol:
- Sample types:
- Serum and plasma
- Sample volume:
- 10 µL
- standards:
- 5 standards, dilute 1:10 prior to use
- Standard range:
- 0 / 20 - 600 ng/mL
- storage:
- 2 - 8 °C
- sensitivity:
- 20 ng/mL
- Species:
- Human
- Products related:
- Anti-Nivolumab (Opdivo®) ELISA
- Additional info:
